Compare IRON & PK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | PK |
|---|---|---|
| Founded | 2017 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 2020 | 2014 |
| Metric | IRON | PK |
|---|---|---|
| Price | $68.20 | $11.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 9 |
| Target Price | ★ $103.18 | $11.22 |
| AVG Volume (30 Days) | 426.0K | ★ 4.1M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 8.82% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $2,791,000,000.00 |
| Revenue This Year | N/A | $2.40 |
| Revenue Next Year | $283.52 | $2.76 |
| P/E Ratio | ★ N/A | $230.10 |
| Revenue Growth | N/A | ★ 2.35 |
| 52 Week Low | $40.00 | $9.84 |
| 52 Week High | $99.50 | $12.39 |
| Indicator | IRON | PK |
|---|---|---|
| Relative Strength Index (RSI) | 51.91 | 67.32 |
| Support Level | $58.13 | $10.82 |
| Resistance Level | $71.53 | $12.36 |
| Average True Range (ATR) | 3.23 | 0.32 |
| MACD | -0.17 | 0.07 |
| Stochastic Oscillator | 46.09 | 98.85 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Park Hotels & Resorts owns upper-upscale and luxury hotels, with 21,042 rooms across 33 hotels in the United States. Park also has interests through joint ventures in another 1,712 rooms in two US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under the Hilton brand. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.